RemeGen Co

RemeGen Co EBITDA per Employee

The EBITDA per Employee of RemeGen Co (688331.SS) as of Oct 27, 2026 is 216,516.09 CNY. In the previous year, EBITDA per Employee was -369,548.59 CNY — a change of -158.59% (higher).

EBITDA per Employee

216,516.09CNY

YoY

-158.59%

Last updated:

EBITDA per Employee of RemeGen Co is 2025 216,516.09 CNY. EBITDA per Employee of RemeGen Co was 2024 -369,548.59 CNY. It decreases by -158.59% higher compared to the previous year.

The RemeGen Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-72,981.39 CNY
Jan 1, 2019
-126,386.85 CNY
Jan 1, 2020
-212,386.25 CNY
Jan 1, 2021
48,870.95 CNY
Jan 1, 2022
-257,802.88 CNY
Jan 1, 2023
-397,564.89 CNY
Jan 1, 2024
-369,548.59 CNY
Jan 1, 2025
216,516.09 CNY
The RemeGen Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
216,516.09CNY-158.59%
-369,548.59CNY-7.05%
-397,564.89CNY+54.21%
-257,802.88CNY-627.52%
48,870.95CNY-123.01%
-212,386.25CNY+68.04%
-126,386.85CNY+73.18%
-72,981.39CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EBITDA per Employee of RemeGen Co is 216,516.09 CNY in 2025.

EBITDA per Employee of RemeGen Co changed from -369,548.59 CNY to 216,516.09 CNY, representing a -158.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — RemeGen Co

All Key Metrics — RemeGen Co